ym 529 has been researched along with Focal Segmental Glomerulosclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Konishi, R; Maeda, S; Morinishi, T; Nawata, A; Ono, E; Takaori, K | 1 |
| Akimoto, T; Ando, Y; Iwazu, K; Kitamura, M; Kobayashi, T; Komada, T; Kusano, E; Morishita, Y; Muto, S; Numata, A; Saito, O; Takemoto, F; Yamamoto, H; Yumura, W | 1 |
2 other study(ies) available for ym 529 and Focal Segmental Glomerulosclerosis
| Article | Year |
|---|---|
Nephrotic syndrome with acute kidney injury due to focal segmental glomerulosclerosis following long-term treatment with minodronate.
Topics: Acute Kidney Injury; Aged, 80 and over; Diphosphonates; Female; Glomerulosclerosis, Focal Segmental; Humans; Imidazoles; Kidney; Male; Nephrotic Syndrome; Proteinuria | 2022 |
Acute kidney injury in a patient with nephrotic syndrome due to focal segmental glomerular nephritis induced by a single oral administration of high-dose bisphosphonate (minodronate).
Topics: Acute Kidney Injury; Administration, Oral; Aged; Bone Density Conservation Agents; Creatinine; Diphosphonates; Glomerulosclerosis, Focal Segmental; Humans; Imidazoles; Male; Nephrotic Syndrome; Osteoporosis | 2013 |